➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Johnson and Johnson
Merck
Express Scripts
McKinsey

Last Updated: February 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ULTOMIRIS

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for ULTOMIRIS

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03920293 Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis Recruiting Alexion Pharmaceuticals Phase 3 2019-04-01 The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).
NCT04248465 An Efficacy and Safety Study of Ravulizumab in ALS Participants Not yet recruiting Alexion Pharmaceuticals Phase 3 2020-03-01 The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS.
NCT04390464 mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R) Recruiting Cambridge University Hospitals NHS Foundation Trust Phase 4 2020-05-08 TACTIC-R is a randomised, parallel arm, open-label platform trial for investigating potential treatment for COVID-19 disease. While SARS-CoV infection evades detection by the immune system in the first 24 hours of infection, it ultimately produces a massive immune system response in the subgroup of people who develop severe complications. Most tissue damage following infection with COVID19 appears to be due to a later, exaggerated, host immune response (Gralinski and Baric 2015). This leads to lung and sometimes multi-organ damage. Most people who develop these severe complications still have virus present in their respiratory tract at the time-point when the disease starts to evolve. Immune modulation in the presence of active infection has potential to cause more harm than benefit. Safety considerations when studying immune modulation strategies are paramount. Therefore, this study proposes to assess the efficacy of immunomodulatory agents that target dysregulated immune response that drive the severe lung, and other organ, damage. The medications investigated for efficacy in this trial are Baricitinib and Ravulizumab. Reference: Gralinski and Baric 2015. Molecular pathology of emerging coronavirus infections. J Pathol 2015: 235: 185-195; DOI: 10.1002/path.4454
NCT04543591 Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant Not yet recruiting Alexion Pharmaceuticals Phase 3 2020-09-01 This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab in adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). In Stage 1 of the study, the dosing regimen for participants with HSCT-TMA will be confirmed. In Stage 2, participants will be randomized to receive either ravulizumab plus best supportive care or best supportive care only. The treatment period is 26 weeks followed by a 26-week off-treatment follow-up period.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ULTOMIRIS

Condition Name

Condition Name for ULTOMIRIS
Intervention Trials
Thrombotic Microangiopathy 2
Covid19 2
Amyotrophic Lateral Sclerosis 1
ALS 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ULTOMIRIS
Intervention Trials
Thrombotic Microangiopathies 3
Vascular Diseases 2
Myasthenia Gravis 1
Glomerulonephritis, IGA 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ULTOMIRIS

Trials by Country

Trials by Country for ULTOMIRIS
Location Trials
United States 4
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ULTOMIRIS
Location Trials
Massachusetts 1
Ohio 1
Nevada 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ULTOMIRIS

Clinical Trial Phase

Clinical Trial Phase for ULTOMIRIS
Clinical Trial Phase Trials
Phase 4 1
Phase 3 5
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ULTOMIRIS
Clinical Trial Phase Trials
Not yet recruiting 5
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ULTOMIRIS

Sponsor Name

Sponsor Name for ULTOMIRIS
Sponsor Trials
Alexion Pharmaceuticals 5
Cambridge University Hospitals NHS Foundation Trust 1
Brigham and Women's Hospital 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ULTOMIRIS
Sponsor Trials
Industry 5
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Johnson and Johnson
Harvard Business School
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.